Postmenopausal hormone therapy is widely used to prevent diseases. This is not, however, based on the kind of evidence that is normally required of a preventive drug therapy: it is based on intermediary outcomes of trials and non-experimental studies. Many reasons can be postulated for the fact that we know little of this old and widely used therapy. To remedy the current situation, we should encourage randomised controlled trials, reveal the insufficiency of the current evidence, and challenge the drug industry's biased influence.
The use of female sex hormone drugs to treat menopausal symptoms and to delay ageing is an old practice, and even its application for preventing diseases has existed for more than two decades. The terms &dquo;hormone replacement therapy&dquo; (HRT) and &dquo;estrogen replacement therapy&dquo; are established terms. However, because these terms imply that something is lacking and take a stand on the unresolved question of whether menopause is a natural part of women's life-cycle or is a state of deficiency, I prefer the terms &dquo;postmenopausal hormone therapy&dquo; (PHT) and &dquo;postmenopausal estrogen therapy&dquo; (EHT) . The purpose of PHT and EHT is either to treat symptoms and diseases or to prevent them or prevent ageing.
From the public health point of view prevention of diseases is an interesting one and is a typical example of prevention by drugs (1) . Estrogens and progestins influence most bodily systems, and many diseases of public health importance are on the list of those said to be either prevented or caused by PHT: different cancers, myocardial infarction, stroke, (other) thromboembolic diseases, diabetes, gallbladder disease, Alzheimer's disease (dementia), fractures, hysterectomy, overall mortality.
The level of use varies across different countries, but in most countries a steady increase in use has occurred (2) . Physicians, especially gynecologists, value PHT more than do women and women often use it for a shorter period than recommended. In Finland in 1996, over one-third of women aged 50 -59 years used PHT at the time they were interviewed, and many had used it previously.
The arguments for and against PHT have varied over time. This has repercussions for the interpretation of epidemiological studies, because physicians' views have had an influence on selection of which type of women should be prescribed PHT. For example, in the 1970s women with cardiovascular diseases were recommended to avoid PHT, whereas since the late 1980s they are being recommended to have PHT. In the last decade common expert recommendations have been that all postmenopausal women (without contraindications), or all having increased risk either for osteoporosis or cardiovascular diseases, should be prescribed PHT, but occasionally more conservative recommendations have surfaced. Some experts have calculated the usefulness of PHT based on women's risk-profiles and the assumed benefits for each disease.
Two surveys in Finland in 1989 and 1995 (3) suggest that the opinions of gynecologists and general practitioners became more positive in terms of PHT preventing cardiovascular diseases and more reserved in terms of breast cancer. A good indicator of expert opinions is the use of PHT by female physicians themselves, which is much higher than that of the population they serve (2) . The recommendations has yet to be seen.
The notion of preventing age-related diseases with hormone therapy is not, however, based on the kind of evidence that is normally required of a preventive drug therapy. Preventive use of hormone therapy has arisen as a result of intermediary outcomes of trials, as well as from non-experimental studies comparing exposed and non-exposed women. There is a large number of such studies (see, e.g., reviews and recent studies: 5 -15) and their results are relatively uniform: hormone therapy users have fewer fractures, fewer heart diseases (impact on thrombotic diseases is negative), less Alzheimer's disease, and more uterine and breast cancer. Relation to other diseases is less clear. Trials on intermediary variables, e.g. osteoporosis and blood lipid changes, support the epidemiological findings on diseases. Time-trend analysis (16) does not support the claim of beneficial effects of postmenopausal therapy.
Because of selection bias, non-experimental evidence is not, however, sufficient to prove the usefulness of hormone (10, 11, 17, 18) . It is likely that women who already take care of their health and/ or have a good health prognosis are more likely to begin and continue PHT than other women. It is also possible that physicians have been unwilling to prescribe hormones to women who are ill or who are at high risk for cancer or cardiovascular diseases or who have metabolic diseases. Osteoporotic women, who are more likely than others to be on PHT, are at lower risk for breast cancer than other women (19) .
Another factor that is difficult to control in nonexperimental studies is treatment compliance and attitudes towards healthcare. Nor can the overall health outcomes be judged from laboratory values. The importance of selection bias is well illustrated by the results of two reports based on clinical trials, both challenging the notion of the protective effect of hormone therapy; one was based on unintended effects (20, 21) , and the other on treatment of sick women (4) . The need for controlled trials on hormone therapy has been acknowledged. Two trials on healthy women have been started: The Women's Health Initiative in the USA and WISDOM in Europe.
Even if we knew the average efficacy of PHT, before a recommendation on prophylactic PHT can be formulated, we should also know about the effectiveness of PHT, the right target groups, long-term safety, its value compared to alternative prevention strategies, and costs. Usually it is poor public policy to prevent a disease with a method that causes another disease, and methods beneficial for all aspects of health should be sought, for preventive purposes. We already know many ways to prevent, for example, cardiovascular diseases and fractures.
Many reasons can be postulated for the fact that we know so little about such an old and widely used therapy. One line of explanation is the complexity of the issue: postmenopausal and menopausal hormone therapies are used for different indications and yield different effects. Studies have included different target groups, many different drugs and doses, and different modes and duration of therapy. The other line of explanation involves social reasons, such as the disinterest in older women and commercial and professional interests. Drug firms and some other industry and care providers benefit financially from the use of PHT. Scientists who provide commercially valuable data or who conduct research believed to be of great health importance gain professionally. Gynecologists have new customers and more prominent status when providing services believed to be of public health importance. Commercial and professional interests work via biases in conducting research and in the dissemination of results.
To improve healthcare for older women, we should encourage and facilitate random, controlled trials on the health effects of postmenopausal therapy, reveal the insufficiency of the current evidence, distribute this information to practicing physicians as well as to women, and challenge the drug industry's biased influence. In addition, there should be professional debate around these social and public health policy issues to encourage research and program formation around them. We should define the interest groups and their motives, and what should be recommended while waiting for the results of rigorous research. Furthermore, we should address the question of whether it is good public policy to prevent one disease with a method causing another, whether mass prevention with drugs is harmful for attempts to encourage healthy behavior, how the current imbalance in supporting research and distributing information could be corrected, and how omission versus commission errors and professional ethics are related.
